序号(S/N) | 时间/Date | 题目/Topic | 讲者/Speaker | 单位/Institution | ||
---|---|---|---|---|---|---|
1 | 11:35-11:43 |
Neoadjuvant radiohormonal therapy for oligo-metastatic prostate cancer: safety and efficacy outcomes from an open-label, dose-escalation, single-center, phase I/II clinical trial |
|
|||
2 | 11:43-11:51 |
PD-1 inhibitor Plus Anlotinib for Metastatic Castration Resistant Prostate Cancer: A Real-World Study |
|
|||
3 | 11:51-11:59 |
The action of IGF-1/IGF-1R signal in the progression and thearpy of prostate cancer |
|
|||
4 | 11:59-12:07 |
Predictive value of CRMP4 methylation signature for Gleason Upgrading in Low-risk Prostate Cancer: a retrospective analysis and multi-institutional validation study |
|
|||
5 | 12:07-12:15 |
Loss of CMTM6 promotes DNA damage-induced cellular senescence and antitumor immunity |
|
|||
6 | 12:15-12:23 |
SCNA burden may not be optimal surrogate for response to ICIs |
|
|||
7 | 12:23-12:28 |
Discussion |